Vesalius Cardiovascular Closes $1M Seed Investment Round – Plans Series-A Financing by End of Year

Prevail Drug Coated Balloon Catheter Launches in Europe

Prevail Drug coated balloon catheter is used during percutaneous coronary intervention procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease.

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

May 28, 2020

Vesalius Cardiovascular Inc. has announced the closing of a $1 million seed financing round to accelerate the engineering of its mitral valve repair device called Calla TC3.

The Vesalius unique concept marries surgery and cardiology to deliver a percutaneous treatment for mitral valve prolapse (also known as degenerative mitral regurgitation), a serious and very common heart valve disease.

“We use proven surgical principles to design and build Calla TC3, an innovative device able to reproduce the effect of surgical valve repair. More importantly, our device is delivered during a transcatheter intervention, requiring a small skin puncture to the leg of the patient and subsequently eliminating the need for open-heart surgery” stated Dr. Peter Skarsgard, Vesalius’ President, co-founder, and inventor of the device. “This financing round will enable the Company to accelerate the engineering phase and reach animal testing by early 2019”.

Vesalius Cardiovascular is developing a surgical implantable to repair the mitral valve without heart surgery. While the gold standard treatment remains open heart surgery, a large number of patients cannot undergo surgery because of the associated risks. Therefore, there exists an unmet clinical need.

The Vesalius device will allow all patients to be treated while eliminating the burden of open-heart surgery.

“Imagine the patient checking into the hospital for treatment on a Friday, returning home on Saturday, and back to normal activities on Monday” noted Vincent Ledoux, COO and co-founder of Vesalius. “The Company will be able to achieve 2 major milestones in 2018 and prepare for a Series A round by end of the year”.

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.